WILMINGTON, Mass., Jan. 29, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that Pacific Air Cargo has purchased its first QS-B220™ desktop explosives trace detector (ETD). This sale is the most recent in a series of orders resulting from Implant Sciences exhibiting its QS-B220 explosives trace detector at Air Cargo 2013.

Air Cargo 2013 took place in March 2013 and is the premier annual trade show and conference for the AEMCA (Air & Expedited Motor Carriers Association), the AfA (Airforwarders Association), the XLA (Express Delivery & Logistics Association), and ACI-NA (Airports Council International – North America), all of whom co-host Air Cargo as a service to the industry.

Pacific Air Cargo CEO, Beti Ward, commented, “We heard about the QS-B220 from a colleague who attended Air Cargo, where they saw the QS-B220 demo and were very impressed. After evaluating the QS-B220’s performance metrics and total cost of ownership, it was clear to us that this is the TSA-qualified ETD we want to use at Pacific Air Cargo.”

“Air cargo purchasers who get exposure and familiarity with our QS-B220 see the clear value in our ETD and this directly results in purchases. Attending industry trade shows is a key component of our sales and marketing strategy. This is the most recent in a series of orders that resulted from Air Cargo 2013 and we look forward to participating in Air Cargo 2014 this year,” commented Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones.

Founded in 2000, Pacific Air Cargo (PAC) possesses extensive experience and maintains an outstanding success record servicing the Honolulu and Pacific region cargo market. The loyalty and confidence of PAC’s customers has resulted in the annual shipment of more than 80 million pounds of cargo and has allowed them to be one of the fastest growing companies in the industry.

About Pacific Air Cargo

Pacific Air Cargo provides exclusive express air cargo service between Los Angeles and Honolulu, including service to Pago Pago and American Samoa, utilizing Boeing 747 freighters. Pacific Air Cargo and its predecessor during the 1990’s, has been the mainstay for heavy freight service into the State of Hawaii for decades. Pacific Air Cargo has specialized in the precious perishable markets with which to supply food to the markets of Hawaii as well as the large and bulky freight that still must reach its destination in a timely manner. PAC is supported by a majority of domestic and international freight forwarders, integrators and airlines which has significantly contributed to the company’s ongoing success.

Pompano Beach, Jan. 27, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (NASDAQ:DSKX), a leading developer of personal care products, today announced it has appointed Aptiv Solutions as its clinical research organization (CRO) for its proprietary topical prescription treatment. If approved the drug will be positioned as frontline therapy in the fight against hair loss, a condition that affects nearly half of the population.

Aptiv Solutions will prepare DS Healthcare’s Investigational New Drug Application (IND), for its proprietary topical hair loss treatment, for submission to the United Stated Food and Drug Administration (FDA). An IND is a request for the FDA’s authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S. To date, only one other topical treatment for hair loss has been approved by the FDA. Aptiv Solutions will also conduct a Gap analysis, to ensure that DS Healthcare’s operations are in line with regulatory requirements for drug approval.

Aptiv Solutions is a leading global CRO with extensive global drug development and trial management expertise. Aptiv Solutions has conducted over 2,600 clinical trials and assisted in over 140 FDA and European Union drug and biologic approvals, as well as over 700 medical device approvals and clearances. DS Healthcare recently announced its intention to submit an IND to the FDA. The move follows the Company’s patent application filing with the United States Patent and Trademark Office for its prescription hair loss treatment invention.

“Our intention is to move the development of our prescription-grade hair loss product at a swift pace. Aptiv Solutions has been central to the successful development, clinical trials, and subsequent regulatory approval of numerous market leading products and we are pleased to have their support as our CRO,” commented DS Healthcare President and CEO, Daniel Khesin.

About Aptiv Solutions

Aptiv Solutions is a global development services company focused on enhancing clinical trial decision-making, efficiency and productivity for pharmaceutical, biotech and medical device sponsors. It is the only CRO to offer design, simulation and execution of adaptive clinical trials and a novel statistical sampling approach to risk-based monitoring. These services span the entire product development cycle from first in human through regulatory approval to post-marketing. Aptiv Solutions has more than 850 professionals in North America, Eastern and Western Europe, Israel and Japan. Learn more at www.aptivsolutions.com.

JERUSALEM, Jan. 30, 2014 /PRNewswire/ — Oramed Pharmaceuticals Inc. (ORMP), a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration (FDA) IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.

30 patients with type 2 diabetes took part in the trial in an in-patient setting for one week. Endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated against a placebo control. For full information on the Phase 2a trial design and endpoints please see Clinical Trials*. Further information on the safety results of the Phase 2a clinical trial can be found on Oramed’s website. Full results are expected to be presented at a scientific conference in the future.

“We are extremely pleased with the results which give a solid validation for Oramed’s platform technology in general and our oral insulin program in particular,” stated Oramed CEO Nadav Kidron. “Following on the results from this type 2 diabetes study we are gearing up to start a multi-center Phase 2b study later this year. We are also excited about the potential of this drug for type 1 diabetes and plan to initiate a Phase 2a FDA study for this indication in the near term.”

About ORMD-0801 Oral Insulin

Oramed’s ORMD-0801 is an orally ingestible insulin capsule for the early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite. Moreover, orally administered insulin has the potential benefit of enhanced patient compliance at this crucial stage as well as the advantage of mimicking insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.